COVID-19 Associated Collapsing FSGS in an APOL1 Homozygous Transplant Recipient After Successful COVID Vaccination: A Case Report

Transplant Proc. 2022 Jul-Aug;54(6):1543-1546. doi: 10.1016/j.transproceed.2021.11.001. Epub 2021 Nov 12.

Abstract

Organ transplant recipients exhibit lower rates of immune response to coronavirus disease 2019 (COVID-19) vaccination. Even when they do mount a demonstrable antibody response, it is unclear what degree of protection is conferred against the myriad potential complications of COVID-19 infection. We present here a case of a kidney transplant recipient who was homozygous for APOL1 risk alleles on low-dose immunosuppression who developed an antibody response to COVID-19 vaccination and subsequently acquired COVID-19 infection. Although she experienced relatively minor effects in other organ systems, she developed severe collapsing focal segmental glomerulosclerosis that left her dependent on hemodialysis on hospital discharge. This suggests that COVID-19 vaccination may not provide protection from infection-associated focal segmental glomerulosclerosis in patients with APOL1 risk alleles.

Publication types

  • Case Reports

MeSH terms

  • Apolipoprotein L1 / genetics
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Female
  • Glomerulosclerosis, Focal Segmental* / chemically induced
  • Humans
  • Transplant Recipients
  • Vaccination / adverse effects

Substances

  • APOL1 protein, human
  • Apolipoprotein L1
  • COVID-19 Vaccines